NSE · ACUTAAS · Pharmaceuticals
Acutaas Chemicals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹322 Cr with net profit ₹76 Cr — a 23.54% net margin, versus 32.5% the period before.
Shareholding
As of 2026-06-30
- Promoter32.66%
- Public26.17%
- FII21.61%
- DII19.56%
1,25,569 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.32× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #2 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,04,902 Cr | 272.64 | 12.2 | 15.32% | 24.32% |
| Acutaas Chemicals Limited(this company) | ₹27,130 Cr | 205.95 | 16.41 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,735 Cr | 116.31 | 13.27 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,672 Cr | 130.32 | 2.19 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,739 Cr | 67.72 | 2.41 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,721 Cr | 110.99 | 4.74 | 12.98% | 11.5% |
| Hikal Limited | ₹2,725 Cr | 188.89 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,254 Cr | 249 | 9.21 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,000 Cr | 148.29 | 6.08 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,326 Cr | 67.64 | 3.18 | 17.67% | 13.66% |
AI analysis
AI-generated · google/gemini-2.5-flashAcutaas Chemicals Limited has a market capitalization of Rs 29934 Cr. The company reported a revenue of Rs 1023.8 Cr with a growth of 40.3% and a profit margin of 26.6%. Its EPS stands at 43.51, and the stock trades at a PE ratio of 227.23. The book value per share is Rs 201.97. Acutaas Chemicals Limited's debt to equity ratio is 0.12, with a dividend yield of 7%. The company has reported a return on equity (ROE) of 21.54% and a return on capital employed (ROCE) of 28.77%.
Positives
- +Revenue growth of 40.3% indicates expansion in business operations.
- +Debt-to-equity ratio of 0.12 is low, suggesting limited financial leverage.
- +Return on Capital Employed (ROCE) of 28.77% demonstrates efficient use of capital.
- +Dividend yield of 7% provides a notable return to shareholders.
Negatives
- −The promoter shareholding has decreased from 49.71% in June 2021 to 32.66% in June 2026.
- −The company is under LT-ASM surveillance, which may indicate potential risks or scrutiny.
- −The trailing twelve months EPS is not available for assessment after March 2026.
Financial Performance
Acutaas Chemicals Limited reported a revenue of Rs 1023.8 Cr, reflecting a growth of 40.3%. The company's net profit margin was 26.6%. The most recent annual data for Mar 2026 shows revenue of Rs 421.77 Cr and net profit of Rs 137.07 Cr. Quarterly results for Mar 2026 recorded revenue of Rs 432.75 Cr and a net profit of Rs 131.76 Cr.
Profitability & Returns
The company's profit margin stood at 26.6%. Acutaas Chemicals Limited achieved a return on equity (ROE) of 21.54% and a return on capital employed (ROCE) of 28.77%. The earnings per share (EPS) for the company is Rs 43.51.
Balance Sheet
Acutaas Chemicals Limited maintains a debt-to-equity ratio of 0.12, indicating a low level of debt relative to its equity. The book value per share is Rs 201.97.
Ownership & Pledges
As of June 30, 2026, promoters held 32.66% of the company's shares, with public shareholders holding 26.17%. FIIs held 21.61% and DIIs held 19.56%. Institutions collectively held 41.16%. There is no promoter share pledge reported.
Regulatory & Surveillance
Acutaas Chemicals Limited is currently under LT-ASM surveillance, specifically in ASM Stage 1. This indicates that the stock is subject to enhanced scrutiny by the regulatory authorities.
Data as of — price: 2026-07-29 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.